Navigation Links
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association

S) at 12 weeks compared to baseline. Secondary efficacy endpoints included changes in IPSS Quality of Life (QoL), patients with >/= 30% and >/= 40% improvement in IPSS, uroflow values (Qmax), PVR and prostate volume. Safety analysis included changes in sexual function (IIEF-5), treatment emergent AEs, lab values (including testosterone, PSA) and vital signs. Mean age was 69.1 (range 52 - 85), IPSS 19.8, Qmax 9.7 mL/sec and prostate size (cm3) 41.6 at baseline.

The effects developed rapidly, with noticeable activity at four weeks from starting treatment, were maximal at 12-16 weeks, and persisted for the entire six-month observation period. At 12 weeks all ozarelix-treated groups showed improvement with the greatest improvement in the 15mg +15mg group. Change from baseline vs. placebo in IPSS was 8.5; peak urine flow change from baseline vs. placebo was 4.7; T levels declined transiently, and returned to baseline in most subjects by 4 weeks and all subjects by 6 weeks following dosing. Based on IIEF, there was no effect seen on erectile function.

Ozarelix was well tolerated and demonstrated statistically significant and clinically meaningful efficacy in the treatment of LUTS secondary to BPH. Serious Adverse Events were reported in 4 patients but were not considered treatment related. No systemic allergic reactions were seen, and the injections were well tolerated.

About Ozarelix and Development Alliance with AEterna Zentaris

Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHRH) antagonist administered as an intramuscular injection. In August 2004, Spectrum received an exclusive license from AEterna Zentaris to develop and market ozarelix for all potential indications in North America (including Canada and Mexico) and India.

In addition, Spectrum will receive 50 percent of any upfront and milestone payments, royalties and/or profits from sales of the product in Japan. Japanese rights for all potential oncology
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
(Date:1/14/2014)... Va. , Jan. 14, 2014 Animal Emergency Critical Care, ... Leesburg, Virginia is the first in ... oxygen chamber. Dr. Susan M. Barnes , ... Dr. Barnes and husband, Dr. Cole Taylor , are avid ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner ... Summit , May 14-16, 2014 at the Global Center ... . This is the premier industry ... achievements through open innovation. Participants will learn how world-changing ...
Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... launched ABAS ( Atlas-based Autosegmentation ) 2.0 software, ... Estimation (STAPLE) algorithm to increase contouring accuracy. ABAS—considered ... of anatomy previously defined on a reference image ... structure set fit to the patient anatomy and ...
... Pa., Oct. 1 Encorium Group, Inc. (Nasdaq: ... conducting studies in over 30 countries for many of the ... has extended the expiration date for its pending rights offering ... rights may now be exercised at any time prior to ...
Cached Medicine Technology:Elekta Launches ABAS 2.0 Autosegmentation Software Used to Plan Radiation Therapy in Patients With Cancer 2Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering 2Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering 3Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering 4Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering 5Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering 6
(Date:4/23/2014)... important enzyme pathway that helps prevent new cells from ... that has been directly linked to cancer and other ... that near the end of cell division, the enzyme ... in DNA are fully repaired before the parent cell ... process helps safeguard against some of the most devastating ...
(Date:4/23/2014)... accessible detection methods that can rapidly screen a ... single cell inside that population has been seriously ... , In the Royal Society of Chemistry journal ... he and his coworkers have developed a novel ... protein ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... Washington, April 21, 2014 Five for-profit and ... of $1.25 million in Proof of Concept grants ... ideas into commercial products, the Life Sciences Discovery ... $300,000 Entrepreneur Mentoring Program grant to the Washington ... statewide advisory network to train the next generation ...
(Date:4/23/2014)... also known as Ritalin, may prevent the depletion of ... , a journal of the Association for Psychological Science. ... diet or trying to focus attention on a boring ... one potential explanation for this difficulty: Exerting self-control for ... exert self-control effectively on subsequent tasks. , "It is ...
(Date:4/22/2014)... has been shown to reduce seizures in patients with ... coupled with an innovative electrode placement planning system developed ... elimination of seizures in nearly half of the implanted ... That,s good news for a large portion of the ... whose seizures can,t be controlled with medications and who ...
Breaking Medicine News(10 mins):Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2
... is alright. But there is a flip side too . ... child's risk of developing asthma. The traditional advice that swimming ... a new study seems to indicate. ,Pediatrics, a ... indoor chlorinated pools during their early years have higher rates ...
... to use a particular cell model that mimics the structure of ... model she identified a rogue cell type that may cause cancer ... it is not possible to study what happens in the real ... cultured cells grown outside the body. Through this model we first ...
... that lizard mothers dress their children in different colour patterns, ... face as adults . ,Researchers at the University ... are able to induce different colour patterns in their broods ... they will wear for the rest of their lives. ...
... That is a scary prospect indeed. Canadian health authorities have ... to radiation from radon gas. ,Radon is a ... uranium in soils and rocks. It is considered a leading ... can also build up to dangerous levels inside homes. It ...
... have found that plants 'know' more about their environment than ... can sense the presence of neighbouring plants through changes in ... in the soil, and adjust their own growth accordingly. ... say they have found that plants that are grown alongside ...
... myelin is associated with the early evolution of Huntington's disease. ... Memory Disorders and Alzheimer's Disease Clinic, suggested in the journal ... type of myelin that develops late in life promotes the ... Myelin is the "insulation" that wraps around nerve axons in ...
Cached Medicine News:Health News:Exposure to Chlorinated Swimming Pools Could Increase Asthma Risk in Children 2Health News:Lizard Mothers Dress Their Progeny to Ensure Success in Later Life 2Health News:Lizard Mothers Dress Their Progeny to Ensure Success in Later Life 3Health News:Canadians Urged to Renovate Houses to Check Radon Gas Radiation 2Health News:Canadians Urged to Renovate Houses to Check Radon Gas Radiation 3Health News:Canadians Urged to Renovate Houses to Check Radon Gas Radiation 4Health News:Myelin Associated With Early Evolution of Huntington's Disease 2Health News:Myelin Associated With Early Evolution of Huntington's Disease 3
... for High Throughput Screening (HTS), Analyst ... into HTS by sharing all the ... Analyst AD, fluorescence intensity, fluorescence plarization, ... for seamless integration into robotic environments, ...
... most advanced multi-functional microplate detection system, ... performance without compromising flexibility. ,The ... on the Ultra instrument platform. New ... adds to the flexibility of the ...
... The FLUOstar is a flexible multifunction ... modes in one instrument: fluorescence intensity, time-resolved ... OPTIMA can be equipped with injectors that ... so that fast kinetic cell assays can ...
The basic modular Wallac 1420 VICTOR2 is a manually operated platereader which enables luminometry, fluorometry and photometry measurements to be made....
Medicine Products: